Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olanzapine with Aprepitant, Palonosetron and Dexamethasone for CINV Prevention
NCT02484911Phase 3Completed
- Sponsor
- The First Affiliated Hospital of Harbin Medical University
- Start
- May 2015
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of olanzapine in chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by The First Affiliated Hospital of Harbin Medical University. Primary endpoints: Proportion of Participants Receiving HEC With Complete Response in Overall Phase and Proportion of Participants Receiving MEC With Complete Response in Overall Phase. Started May 2015; status: completed.
02
Drugs
olanzapine
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT02484911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02484911.